Wednesday, March 05, 2025 | 06:07 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Syringes and needles maker put trade margin cap of 75% after NPPA nudge

Pricing regulation on medical devices gains momentum

Pharma
Premium

Centre had a few months ago brought coronary stents and orthopaedic knee implants under price cap

Veena ManiSohini DasAneesh Phadnis New Delhi
About a year since the National Pharma Pricing Authority (NPPA) put a price cap on coronary stents, medical devices industry is making a slow move to self-regulation by capping trade margins. Syringes and needles makers have put a cap of 75 per cent on trade margins, effective Republic Day, to avoid the wrath of pharma pricing regulator. The NPPA put a price cap on coronary stents and orthopaedic implants last year. 

Also, it forced over 15 other device makers to finally put a maximum retail price on devices for the first time to avoid overcharging by hospitals. 

Vimal Khemka, who

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in